Vascular Post Market Review

ENDPOINTS 1. OR experience: suturability, handling, hemostasis, compliance to recipient vessel, blood loss, OR time. 2. In-hospital survival 3. MAE (Stroke, MI, death) 4. 1 Month duplex US scan 5. 6 month duplex US scan Secondary Efficacy Endpoints 1\. Less than 50% stenosis at 6 months (PSV \<150 cm/s) Safety Endpoint Incidence of CardioCel related Major Adverse Cardiac Events (MACE) at 6 months, defined for this study as: * Structural CardioCel failure - aneurysm/dilation * Vasculitis * Leak or pseudoaneurysm * Dehiscence * Thromboembolism * Thrombosis * Haemolysis * Reoperation and explant Review endpoints at 6 months to confirm results meet the expectations of the Principal Investigator. BACKGROUND Rationale for Study: CardioCel's unique strength, pliability, resistance to degradation and calcification make it a promising alternative to synthetic fabrics or other xenographic materials incompletely decellularized or detoxified (aldehyde removal). Device Description: Tissue-engineered CardioCel pericardium is manufactured from bovine spongiform encephalopathy-free pericardium (37). Manufacturing consists of several tissue-engineering processes, which include steps to remove lipids, cells and cell remnants, nucleic acids (DNA, RNA) and Gal epitopes. In addition, cross-linking is achieved with an ultra-low engineered glutaraldehyde concentration to minimise glutaraldehyde cytotoxicity levels (Admedus Ltd. proprietary). Cytotoxicity is further reduced by the ADAPT® anti-calcification process and a non-glutaraldehyde sterilisation and storage solution. CardioCel is US FDA cleared for the repair of cardiac and vascular defects, including intra-cardiac defects; septal defects, valve and annulus repair, great vessel reconstruction, peripheral vascular reconstruction, suture line buttressing and pericardial closure. STUDY DESIGN This is a prospective, non-randomized, single arm study. SCHEDULE OF ASSESSMENTS/DATA COLLECTION ENROLLMENT: 10 subjects to be enrolled per site DURATION OF ENROLLMENT: Patients will be followed for 6 months after CEA procedure. SCREENING A pre-screening procedure may be performed to determine whether the patient meets the inclusion/exclusion eligibility selection criteria. A pre-screened patient will be asked to sign the informed consent form before any study-specific tests or procedures are performed. Subject screening numbers will be assigned at this visit and subjects will be evaluated for eligibility criteria. BASELINE Informed consent will be obtained from all subjects who are potential trial candidates prior to commencement of any study related procedures. The following baseline data will be collected for all subjects prior to procedure: * Patient demographics * Standard of care Physical Examination * Vital Signs (Blood pressure and heart rate only) * Medical history (for cardiovascular risk factors) * Standard of care Clinical Lab tests * Final confirmation of Inclusion/Exclusion Criteria IMPLANT PROCEDURE Patients will undergo a CEA with patch arterioplasty. Patients will be managed according to standard pre-operative, operative, and postoperative care. The following OR Experience data will be collected for all subjects: * Suturability * Handling * Hemostasis * Compliance to recipient vessel * Blood loss * OR time * In-hospital survival * MAE (Stroke, MI, death) FOLLOW-UP VISITS Patients will return for follow-up visits that will include a carotid duplex ultrasound at 1 and 6 months. Follow-up visits may also include a physical examination and adverse event review. The following follow-up data will be collected for all subjects: * Standard of care physical examination * 1 Month duplex US scan- Duplex US scanning for velocity, calibre, occlusion/lesion status * 6 month duplex US scan- Duplex US scanning for velocity, calibre, occlusion/lesion status * MAE (Stroke, MI, death) and AE review at each visit STATISTICAL ANALYSIS \& DATA MANAGEMENT: Principal Investigator plans to follow patients for 6 months and create report (white paper) on OR experiences and 6 month follow-up. The study is a direct observation of 6 month follow-up for patients undergoing CEA with patch arterioplasty. No control group is included in the study, and no comparative analysis is planned. DATA MONITORING Internal monitoring will be conducted periodically. CRF's, source documents, informed consent forms, and study deviations will be included; these findings will be reported to the PI. Deviations will be documented and reported according to IRB policy. Regulatory documents will be audited by the Baylor Research Institute Department of Research Compliance upon request.